Viralytics Ltd (VLA)

Sydney
1.745
0.000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    1.745 - 1.750

VLA Overview

Prev. Close
1.745
Day's Range
1.745-1.75
Revenue
11.29M
Open
1.745
52 wk Range
0-0
EPS
-0.06
Volume
0
Market Cap
485.57M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
651,371
P/E Ratio
-
Beta
-0.42
1-Year Change
0%
Shares Outstanding
278,262,889
Next Earnings Date
-
What is your sentiment on Viralytics Ltd?
or
Market is currently closed. Voting is open during market hours.

Viralytics Ltd Company Profile

Employees
0
Market
Australia

Viralytics Limited, a biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies in Australia and internationally. The company’s lead investigational product is CAVATAK, a proprietary formulation of an oncolytic common cold virus that is in Phase Ib clinical trials for the treatment of melanoma, and lung and bladder cancer; Phase II clinical trials for the treatment of late stage melanoma; and in pre-clinical studies for the treatment of prostate and breast cancer, multiple myeloma, pancreatic cancer, malignant glioma, acute myeloid leukemia, and chronic lymphocytic leukemia. It is also developing EVATAK to treat ovarian, prostate, and gastric cancer. The company was formerly known as Psiron Ltd. and changed its name to Viralytics Limited in December 2006. Viralytics Limited is headquartered in Sydney, Australia. As of June 20, 2018, Viralytics Limited operates as a subsidiary of Merck & Co. Inc.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellNeutralStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong SellSellStrong BuyStrong Buy
SummaryStrong SellStrong SellNeutralStrong BuyStrong Buy
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.